well played... but HXL do have patents on their IP.. so a failed Phase II is certainly a setback, but it may not be the end (I don't invest in biotech - and not interested in looking / comparing further) I would hardly say that 9SP has a successful product either - otherwise retention / renewals would occur
if 9SP is in a better position - it is as you say because they have a lower cash burn... but they are also running out of cash - to the point that being listed next year is not certain. (failure of going concern condition)
I would not put another dime into them... if a CR came along - would you?
9SP Price at posting:
0.4¢ Sentiment: Sell Disclosure: Held
